Do we have enough evidence to support the use of SGLT2 inhibitors for MACE reduction in patients with advance kidney disease?
Doshi, Rajkumar, Meghji, Zahara, Kumar, Ashish, Shariff, Mariam, Adalja, DevinaLanguage:
english
Journal:
European Journal of Internal Medicine
DOI:
10.1016/j.ejim.2019.10.014
Date:
November, 2019
File:
PDF, 574 KB
english, 2019